New Insights Into the FGF23-Klotho Axis

Seminars in Nephrology

Volumn 34, Issue 6, 2014, Pages 586-597

  Olauson, Hannes ^a   Vervloet, Marc G ^b   Cozzolino, Mario ^c   Massy, Ziad A ^d,e   Torres, Pablo Ureña ^f   Larsson, Tobias E ^a,g  

^a KAROLINSKA INSTITUTE   (Sweden)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^e LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Calcium; Chronic kidney disease; FGF 23; Fibroblast growth factor 23; Parathyroid hormone; Phosphate; Vitamin D

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR; KLOTHO PROTEIN; BETA GLUCURONIDASE; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR; PHOSPHATE;

AGING; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; FIBROSIS; HEART LEFT VENTRICLE HYPERTROPHY; HOMEOSTASIS; HUMAN; HYPERPHOSPHATEMIA; KIDNEY INJURY; MINERAL METABOLISM; MOUSE MODEL; NONHUMAN; PHOSPHATE METABOLISM; PROTEIN DEFICIENCY; REVIEW; ANIMAL; BLOOD; CHRONIC KIDNEY FAILURE; COMPLICATION; DEFICIENCY; GENE EXPRESSION REGULATION; GENETICS; HYPERPARATHYROIDISM, SECONDARY; METABOLISM;

ANIMALS; BIOLOGICAL MARKERS; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; GLUCURONIDASE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84915766769     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2014.09.005     Document Type: Review

References (98)

1. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000, 26:345-348.
2. Shimada T., Mizutani S., Muto T., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001, 98:6500-6505.
3. Liu S., Guo R., Simpson L.G., Xiao Z.S., Burnham C.E., Quarles L.D. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 2003, 278:37419-37426.
4. Kuro-o M., Matsumura Y., Aizawa H., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997, 390:45-51.
5. Ichikawa S., Imel E.A., Kreiter M.L., et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Musculoskelet Neuronal Interact 2007, 7:318-319.
6. Tsujikawa H., Kurotaki Y., Fujimori T., Fukuda K., Nabeshima Y. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 2003, 17:2393-2403.
7. Ohnishi M., Nakatani T., Lanske B., Razzaque MS. In vivo genetic evidence for suppressing vascular and soft-tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1,25-dihydroxyvitamin d levels. Circ Cardiovasc Genet 2009, 2:583-590.
8. Ohnishi M., Nakatani T., Lanske B., Razzaque M.S. Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase. Kidney Int 2009, 75:1166-1172.
9. Goetz R., Ohnishi M., Kir S., et al. Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor. J Biol Chem 2012, 287:29134-29146.
10. Sitara D., Kim S., Razzaque M.S., et al. Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet 2008, 4:e1000154.
11. Li Y., He X., Olauson H., Larsson T.E., Lindgren U. FGF23 affects the lineage fate determination of mesenchymal stem cells. Calcif Tissue Int 2013, 93:556-564.
12. Gattineni J., Bates C., Twombley K., et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol 2009, 297:F282-F291.
13. Goetz R., Mohammadi M. Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol 2013, 14:166-180.
14. Shimada T., Hasegawa H., Yamazaki Y., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004, 19:429-435.
15. Ben-Dov I.Z., Galitzer H., Lavi-Moshayoff V., et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007, 117:4003-4008.
16. Krajisnik T., Bjorklund P., Marsell R., et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007, 195:125-131.
17. Urakawa I., Yamazaki Y., Shimada T., et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006, 444:770-774.
18. Olauson H., Lindberg K., Amin R., et al. Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism. J Am Soc Nephrol 2012, 23:1641-1651.
19. Lindberg K., Amin R., Moe O.W., et al. The Kidney is the principal organ mediating Klotho effects. J Am Soc Nephrol 2014, 25:2169-2175.
20. Chen C.D., Podvin S., Gillespie E., Leeman S.E., Abraham C.R. Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci U S A 2007, 104:19796-19801.
21. Matsumura Y., Aizawa H., Shiraki-Iida T., Nagai R., Kuro-o M., Nabeshima Y. Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein. Biochem Biophys Res Commun 1998, 242:626-630.
22. Hu M.C., Shi M., Zhang J., et al. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 2010, 24:3438-3450.
23. Chang Q., Hoefs S., van der Kemp A.W., Topala C.N., Bindels R.J., Hoenderop J.G. The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science 2005, 310:490-493.
24. Haenzi B., Bonny O., Masson R., et al. Loss of Memo, a novel FGFR regulator, results in reduced lifespan. FASEB J 2014, 28:327-336.
25. Kurosu H., Yamamoto M., Clark J.D., et al. Suppression of aging in mice by the hormone Klotho. Science 2005, 309:1829-1833.
26. Liu H., Fergusson M.M., Castilho R.M., et al. Augmented Wnt signaling in a mammalian model of accelerated aging. Science 2007, 317:803-806.
27. Doi S., Zou Y., Togao O., et al. Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem 2011, 286:8655-8665.
28. Yamazaki Y., Okazaki R., Shibata M., et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002, 87:4957-4960.
29. Smith E.R., McMahon L.P., Holt S.G. Method-specific differences in plasma fibroblast growth factor 23 measurement using four commercial ELISAs. Clin Chem Lab Med 2013, 51:1971-1981.
30. Shimada T., Urakawa I., Isakova T., et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 2010, 95:578-585.
31. Shimada T., Muto T., Urakawa I., et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 2002, 143:3179-3182.
32. Tagliabracci V.S., Engel J.L., Wiley S.E., et al. Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. Proc Natl Acad Sci U S A 2014, 111:5520-5525.
33. Eren M., Boe A.E., Murphy S.B., et al. PAI-1-regulated extracellular proteolysis governs senescence and survival in Klotho mice. Proc Natl Acad Sci U S A 2014, 111:7090-7095.
34. Farrow E.G., Yu X., Summers L.J., et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A 2011, 108:E1146-E1155.
35. Heijboer A.C., Blankenstein M.A., Hoenderop J., de Borst M.H., Vervloet M.G., consortium N. Laboratory aspects of circulating α-Klotho. Nephrol Dial Transplant 2013, 28:2283-2287.
36. Yamazaki Y., Imura A., Urakawa I., et al. Establishment of sandwich ELISA for soluble alpha-Klotho measurement: age-dependent change of soluble alpha-Klotho levels in healthy subjects. Biochem Biophys Res Commun 2010, 398:513-518.
37. Carpenter T.O., Insogna K.L., Zhang J.H., et al. Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. J Clin Endocrinol Metab 2010, 95:E352-E357.
38. Akimoto T., Yoshizawa H., Watanabe Y., et al. Characteristics of urinary and serum soluble Klotho protein in patients with different degrees of chronic kidney disease. BMC Nephrol 2012, 13:155.
39. Shimamura Y., Hamada K., Inoue K., et al. Serum levels of soluble secreted α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis. Clin Exp Nephrol 2012, 16:722-729.
40. Seiler S., Wen M., Roth H.J., et al. Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease. Kidney Int 2013, 83:121-128.
41. Hu M.C., Shi M., Zhang J., et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011, 22:124-136.
42. Saito H., Maeda A., Ohtomo S., et al. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 2005, 280:2543-2549.
43. Lavi-Moshayoff V., Wasserman G., Meir T., Silver J., Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 2010, 299:F882-F889.
44. Isakova T., Wahl P., Vargas G.S., et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011, 79:1370-1378.
45. Stubbs J.R., He N., Idiculla A., et al. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J Bone Miner Res 2012, 27:38-46.
46. Kuro-o M. Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism. Nat Rev Nephrol 2013, 9:650-660.
47. Kato K., Jeanneau C., Tarp M.A., et al. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem 2006, 281:18370-18377.
48. Tsuji K., Maeda T., Kawane T., Matsunuma A., Horiuchi N. Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice. J Bone Miner Res 2010, 25:1711-1723.
49. Carrillo-Lopez N., Roman-Garcfa P., Rodrfguez-Rebollar A., Fernandez-Martfn J.L., Naves-Dfaz M., Cannata-Andfa J.B. Indirect regulation of PTH by estrogens may require FGF23. J Am Soc Nephrol 2009, 20:2009-2017.
50. Liu E.S., et al. Calcitonin administration in X-linked hypophosphatemia. N Engl J Med 2011, 364:1678-1680.
51. Smith R.C., O'Bryan L.M., Farrow E.G., et al. Circulating αKlotho influences phosphate handling by controlling FGF23 production. J Clin Invest 2012, 122:4710-4715.
52. Wolf M., Koch T.A., Bregman D.B. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 2013, 28:1793-1803.
53. Forster R.E., Jurutka P.W., Hsieh J.C., et al. Vitamin D receptor controls expression of the anti-aging klotho gene in mouse and human renal cells. Biochem Biophys Res Commun 2011, 414:557-562.
54. Marsell R., Krajisnik T., Goransson H., et al. Gene expression analysis of kidneys from transgenic mice expressing fibroblast growth factor-23. Nephrol Dial Transplant 2008, 23:827-833.
55. Krajisnik T., Olauson H., Mirza M.A., et al. Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients. Kidney Int 2010, 78:1024-1032.
56. Moreno J.A., Izquierdo M.C., Sanchez-Nino M.D., et al. The inflammatory cytokines TWEAK and TNFα reduce renal klotho expression through NFκB. J Am Soc Nephrol 2011, 22:1315-1325.
57. Mitobe M., Yoshida T., Sugiura H., Shirota S., Tsuchiya K., Nihei H. Oxidative stress decreases klotho expression in a mouse kidney cell line. Nephron Exp Nephrol 2005, 101:e67-e74.
58. Sun C.Y., Chang S.C., Wu M.S. Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation. Kidney Int 2012, 81:640-650.
59. Young G.H., Wu V.C. KLOTHO methylation is linked to uremic toxins and chronic kidney disease. Kidney Int 2012, 81:611-612.
60. Larsson T., Nisbeth U., Ljunggren O., Juppner H., Jonsson K.B. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003, 64:2272-2279.
61. Christov M., Waikar S.S., Pereira R.C., et al. Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int 2013, 84:776-785.
62. Sakan H., Nakatani K., Asai O., et al. Reduced renal α-Klotho expression in CKD patients and its effect on renal phosphate handling and vitamin D metabolism. PLoS One 2014, 9:e86301.
63. Imura A., Tsuji Y., Murata M., et al. alpha-Klotho as a regulator of calcium homeostasis. Science 2007, 316:1615-1618.
64. Brownstein C.A., Adler F., Nelson-Williams C., et al. A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci U S A 2008, 105:3455-3460.
65. Shalhoub V., Shatzen E.M., Ward S.C., et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 2012, 122:2543-2553.
66. Galitzer H., Ben-Dov I.Z., Silver J., Naveh-Many T. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 2010, 77:211-218.
67. Olauson H., Lindberg K., Amin R., et al. Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion. PLoS Genet 2013, 9:e1003975.
68. Faul C., Amaral A.P., Oskouei B., et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011, 121:4393-4408.
69. Six I., Okazaki H., Gross P., et al. Direct, acute effects of Klotho and FGF23 on vascular smooth muscle and endothelium. PLoS One 2014, 9:e93423.
70. Andrukhova O., Slavic S., Smorodchenko A., et al. FGF23 regulates renal sodium handling and blood pressure. EMBO Mol Med 2014, 6:744-759.
71. Fliser D., Kollerits B., Neyer U., et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007 Sep, 18(9):2600-2608. (Epub 2007 Jul 26).
72. Gutiérrez O.M., Mannstadt M., Isakova T., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008 Aug 7, 359(6):584-592. 10.1056/NEJMoa0706130.
73. Jean G., Terrat J.C., Vanel T., et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009 Sep, 24(9):2792-2796. (Epub 2009 Apr 25). 10.1093/ndt/gfp191.
74. Olauson H., Qureshi A.R., Miyamoto T., Barany, et al. Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship?. Nephrol Dial Transplant 2010 Sep, 25(9):3033-3038. (Epub 2010 Apr 5). 10.1093/ndt/gfq191.
75. Parker B.D., Schurgers L.J., Brandenburg V.M., et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010 May 18, 152(10):640-648. 10.7326/0003-4819-152-10-201005180-00004.
76. Isakova T., Xie H., Yang W., et al. Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011 Jun 15, 305(23):2432-2439. 10.1001/jama.2011.826.
77. Kendrick J, Cheung AK, Kaufman JS, et al. HOST Investigators FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol. 2011 Oct;22(10):1913-1922. [Epub 2011 Sep 7]. http://ASN.2010121224/ASN.2010121224.
78. Titan S.M.1, Zatz R., Graciolli F.G., dos, et al. FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol 2011 Feb, 6(2):241-247. (Epub 2010 Oct 21). 10.2215/CJN.04250510.
79. Wolf M., Molnar M.Z., Amaral A.P., et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011 May, 22(5):956-966. (Epub 2011 Mar 24). 10.1681/ASN.2010080894.
80. Lundberg S.1, Qureshi A.R., Olivecrona S., et al. FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy. Clin J Am Soc Nephrol 2012 May, 7(5):727-734. Epub 2012 Mar 1. 10.2215/CJN.10331011.
81. Faul C., Amaral A.P., Oskouei B., et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011 Nov, 121(11):4393-4408. [Epub 2011 Oct 10]. 10.1172/JCI46122.
82. Ix J.H., Katz R., Kestenbaum B.R., et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol 2012 Jul 17, 60(3):200-207. (Epub 2012 Jun 13). 10.1016/j.jacc.2012.03.040.
83. Baia L.C., Humalda J.K., Vervloet M.G., et al. NIGRAM Consortium. Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation. Clin J Am Soc Nephrol 2013 Nov, 8(11):1968-1978. (Epub 2013 Aug 8). 10.2215/CJN.01880213.
84. Ärnlöv J., Carlsson A.C., Sundström J., et al. Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology. Clin J Am Soc Nephrol 2013 May, 8(5):781-786. Epub 2013 Jan 18. PMID: 23335040 [PubMed - indexed for MEDLINE]. 10.2215/CJN.09570912.
85. Floege J., et al. Oral presentation. ASN Kidney Week 2013.
86. Udell J.A., Morrow D.A., Jarolim P., et al. Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. J Am Coll Cardiol 2014 Jun 10, 63(22):2421-2428. (Epub 2014 Apr 9). 10.1016/j.jacc.2014.03.026.
87. Isakova T., Barchi-Chung A., Enfield G., et al. Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. Clin J Am Soc Nephrol 2013, 8:1009-1018.
88. Ketteler M., Biggar P.H. Use of phosphate binders in chronic kidney disease. Curr Opin Nephrol Hypertens 2013, 22:413-420.
89. Koizumi M., Komaba H., Nakanishi S., Fujimori A., Fukagawa M. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2012, 27:784-790.
90. Goetz R., Nakada Y., Hu M.C., et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A 2010, 107:407-412.
91. Gozgit J.M., Wong M.J., Moran L., et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 2012, 11:690-699.
92. Shibata K., Fujita S., Morita H., et al. Association between circulating fibroblast growth factor 23, α-Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients. PLoS One 2013, 8:e73184.
93. Andrukhova O., Zeitz U., Goetz R., Mohammadi M., Lanske B., Erben R.G. FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2-SGK1 signaling pathway. Bone 2012, 51:621-628.
94. Farrow E.G., Davis S.I., Summers L.J., White K.E. Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol 2009, 20:955-960.
95. Lim K., Lu T.S., Molostvov G., et al. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 2012, 125:2243-2255.
96. Fang Y., Ginsberg C., Seifert M., et al. CKD-Induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder. J Am Soc Nephrol 2014, 25:1760-1773.
97. Scialla J.J., Lau W.L., Reilly M.P., et al. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 2013, 83:1159-1168.
98. Lindberg K., Olauson H., Amin R., et al. Arterial klotho expression and FGF23 effects on vascular calcification and function. PLoS One 2013, 8:e60658.